The idea of combining Sovaldi and Ledipasvir would seem to be unable to attain the non-obviousness threshold for a patent; however, I thought AMZN’s “one-click checkout” idea was obvious, so what do I know?
p.s. I don’t think any of this litigation says anything in particular about how well ABBV/ENTA’s HCV regimen will sell.
ABBV filed the patent even before GILD acquired VRUS. GILD filed the patent before VRUS acquisition as well. PTO had granted to ABBV but not to GILD yet.
Sounds like we'll see some price competition soon.
Market Data 
Markets 
AI
